IRulya Therapeutics (IRLA) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IRulya Therapeutics is the larger company by market cap ($432.4 million vs $405.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRLA | TVGN |
|---|---|---|
| Share price | $39.88 | $5.90 |
| Market cap | $432.36M | $405.20M |
| 1-day change | -0.15% | -6.35% |
| YTD return | — | -64.35% |
| 1-year return | — | -73.84% |
| EPS (TTM) | $-162.79 | $-7.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-83.98M | $-26.28M |
| 52-week high | $910.00 | $24.90 |
| 52-week low | $15.10 | $3.64 |
| Distance from 52-week high | -95.62% | -76.31% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +90.90% | — |
| Average volume | 63.03K | 7.94K |
| Shares outstanding | 10.84M | 68.68M |
| Employees | 38 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
IRLA vs TVGN FAQ
Which is bigger, IRulya Therapeutics or Tevogen?
IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $405.20M for Tevogen (TVGN).
Are IRulya Therapeutics and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.